- Received January 17, 2021
- Accepted February 23, 2021
- Publication April 02, 2021
- Visibility 3 Views
- Downloads 1 Downloads
- DOI 10.18231/j.ijmr.2021.014
-
CrossMark
- Citation
Antibiotic susceptibility patterns of Pseudomonas sp. isolated from various clinical samples at a tertiary care hospital at Dewas in Madhya Pradesh, India
Introduction
Pseudomonas is an ultimate example of the opportunistic nosocomial pathogen, which in immuno-compromised patients causes a broad range of infections and contributes to severe morbidity. The mortality due to nosocomial pseudomonal pneumonia is around 70 percent, despite therapy.[1] Sadly, P. aeruginosa displays resistance to several antibiotics, thus endangering the option of effective therapy.[2] In isolates that are multidrug tolerant, the relative contributions to phenotypic multidrug resistance from various molecular pathways are not well-known. While several surveillance studies have been performed over the years to control the resistance of Pseudomonas sp. to different antimicrobial agents, studies identifying trends in concurrent resistance to various antibiotics over time are rare.[3], [4] One of the most serious complications associated with Pseudomonas is antibiotic resistance. Due to their ability to be naturally resistant to several pathogens, a limited number of antibiotics are successful.[5] Most gram-negative bacteria (including Pseudomonas) are responsible for the production of ESBL, which shows resistance to many antibiotics of new generations.[6] Very little data is available regarding the pattern of resistance of antibiotic drugs to Pseudomonas sp. in the Dewas, Madhya Pradesh. Therefore, we study the pattern of antibiotic resistance of Pseudomonas sp., as it is the first study in the tertiary care hospital of the Dewas region of Madhya Pradesh, India.
Materials and Methods
The present study was done at the Amaltas Institute of Medical Sciences, Dewas, Madhya Pradesh. It begins from February 2019 to December 2019. In this study total of 82 strains of Pseudomonas sp. were isolated from different clinical samples (Urine, sputum, pus, fluid, and Catheter tip samples) in the tertiary care hospital. Identification of Pseudomonas sp. was done by biochemical tests. Antibiotic susceptibility test (AST) method was done by Kirby-Bauer disc diffusion method as per CLSI (clinical and laboratory standards institute) criteria.[7] All the analysis was performed using the simple percentage method.[7], [8]
Identification of Pseudomonas sp.
All clinical samples collected were inoculated aseptically on MacConkey agar and Blood agar media plates in case of urine and pus samples while an additional chocolate agar plate was used in case of sputum samples which were incubated at 37°C for 24 Hrs. Urine samples were inoculated by using a 4mm inoculating loop. In the case of the urine sample, 105CFU/ml of growth was considered for significant bacteriuria. Further Pseudomonas sp. was identified by cultural characteristics, morphological characteristics.[9]
Identification of Pseudomonas sp. was done by biochemical tests.
Biochemical tests:- Pseudomonas sp. indicated Oxidase positive reaction. In mannitol test showed strong motility. The color of citrate converted to blue from green indicated a positive reaction. The urease tube remains unchanged indicates a negative reaction. Triple sugar iron (TSI) indicated alkaline slant /no change in the butt. Species identification of Pseudomonas was performed by the Oxidative-Fermentative (O-F) test for Glucose, sucrose, lactose, and mannitol; Liquefaction of gelatin, by beta hemolysis on a blood agar plate and test for nitrate reduction. The urease hydrolysis is also used for its identification. Other tests include decarboxylation of Arginine, Lysin, and Ornithine. The growth at 35 ⁰C and at 42⁰ C for a time duration of 18-24 hours on two tubes of trypticase soy agar (TSA).[10]
Antibiotic susceptibility test
Antibiotic susceptibility test (AST) method was done by Kirby-Bauer disc diffusion method on Pseudomonas sp. following the guidelines of the Clinical Laboratory Standards Institute 2015. [11] First, the inoculums were prepared for AST with the help of nutrient broth by taking 5/6 colony of Pseudomonas sp. that matched to 0.5 McFarland standard (1.5x108CFU/ml) within 15 minutes, a sterile cotton swab was dipped into the inoculums suspension and pressed inside the wall of the tube above the fluid level, and inoculate over the dried surface of Mueller Hinton Agar (MHA) plate. After 3-5 minutes antibiotic discs were applied and gently pressed down to ensure complete contact with agar. The antibiotic disc used for AST in present study were purchased from Hi-media laboratories; co-trimoxazole (25µg), ciprofloxacin (5µg), ceftazidime (30µg), cefixime(30µg), gentamicin (10µg), amikacin(30µg), meropenem(10µg), cefoperazone/sulbactam (75/3030µg), piperacillin -tazobactam(100/10µg), colistin(10µg), polymyxin-B(300unit), piperacillin (100µg), tobramycin(10µg), cefotaxime(30µg) and amoxicillin/clavulanic acid (30µg). Zone of inhibition was measured in mm was concluded with interpretative criteria CLSI 2015 [11] and isolates were sensitive, intermediate, and resistant. Pseudomonas aeruginosa ATCC-27853 was used as a control strain. [11]
Identification of extended-spectrum β-lactamase (ESBL) producing strains
ESBL producers isolates were identified as resistant to antibiotics like ceftazidime, cefotaxime, and ceftriaxone in AST.[12] Further confirmation for ESBL producing Strains was done by placing the amoxicillin/clavulanic acid at the center and on sides, ceftazidime and cefotaxime were placed 25 mm apart from center to center on inoculated MHA plate. The incubation of the MHA plate was done at 37°C for 18-24 hrs. The inoculums that showed zone of inhibition with synergism in between amoxicillin/clavulanic acid and cefotaxime or ceftazidime was confirmed ESBL producers.[8]
Ethical clearance
No ethical clearance was required in this study as it was done on stored refrigerated bacterial isolates.
Results
The total number of isolates of Pseudomonas sp. collected were 82. Gender wise distribution of isolates were male (56.01%) and female (43.9%) patients, as shown in figure 1(A). The sample distribution for collected isolated was Pus 54.87%, Urine 32.92%, Sputum 6%, Fluid 2.43% and catheter tip 3.65%, as shown in figure 1(B). Out of total 82 isolates of 54(65.85%) isolates of Pseudomonas sp. collected from inpatients (IPD samples) whereas 28(34.15%) isolates collected from outpatients(OPD samples)as shown in figure 2. The highest number of isolates of Pseudomonas sp. were collected from patients at age interval between 31 to 45 years (33 isolates), as shown in figure 3. In every age group isolates collected from male patients was greater than female patients. Morphology of Pseudomonas sp. are in gram-negative rods belongs to the family of Enterobacteriaceae, as shown in figure 4. Sensitivity was seen 100% (n=82) in colistin and polymyxin-B, 86.58% (n=71) in meropenum, 82.92% (n=68) in piperacillin -tazobactam, 68.29%(N=56) in tobramycin, 67.07% (n=55) in gentamicin, 64.63%(n=53) in amikacin, 58.58%(n=48) in piperacillin, 56.09%(n=46) in ceftazidime and 51.21%(n=42) in ciprofloxacin, as shown in the figure 6. Resistance was seen 80.48% (N=66) in co-trimoxazole, 82.92% (n=68) in cefixime, 59.75% (n=49) in cefoperazone/sulbactam, 39.02%(n=32) in ciprofloxacin and 36.58%(n=30) in piperacilin, as shown in the figure 7. The maximum number of MDR strains were isolated from the pus samples (n=18) as compared to other samples. MDR strains were seen higher in males than females in the case of pus samples, whereas females were seen in greater numbers than males in urine samples, as shown in figure 8(B). The total number of ESBL producing strains of Pseudomonas sp. in clinical samples was 30.48%(n=25). The distribution of ESBL strains of Pseudomonas sp. in clinical samples was pus 60%(n=25), urine 36%(n=9), and catheter tip 4%(n=4), as shown in figure 9. The ESBL strains were seen higher in number in the pus sample as compared to other samples. From the total strains, the number of Peudomonas aeruginosa strains (n=57, 69.51%) was seen as greater than other species, as shown in figure 10.
|
Senstivity |
Intermediate |
Resistance |
||||
|
Antibiotic Name |
NS |
% |
NI |
% |
NR |
% |
|
Co-trimoxazole |
11 |
13.41 |
5 |
6.09 |
66 |
80.48 |
|
Ciprofloxacin |
42 |
51.21 |
8 |
9.75 |
32 |
39.02 |
|
Ceftazidime |
46 |
56.09 |
6 |
7.31 |
30 |
36.58 |
|
Cefixime |
4 |
4.87 |
10 |
12.19 |
68 |
82.92 |
|
Gentamicin |
55 |
67.07 |
7 |
8.53 |
20 |
24.39 |
|
Amikacin |
53 |
64.63 |
8 |
9.75 |
21 |
25.6 |
|
Meropenem |
71 |
86.58 |
4 |
4.87 |
7 |
8.53 |
|
Cefoparazone-salbactam |
21 |
25.6 |
12 |
14.63 |
49 |
59.75 |
|
Piperacillin-tazobactam |
68 |
82.92 |
3 |
3.65 |
11 |
13.41 |
|
Colistin |
82 |
100 |
0 |
0 |
0 |
0 |
|
Polymyxin-B |
82 |
100 |
0 |
0 |
0 |
0 |
|
Piperacillin |
48 |
58.53 |
4 |
4.87 |
30 |
36.58 |
|
Tobramycin |
56 |
68.29 |
7 |
8.53 |
19 |
23.17 |
Discussion
In the present study, maximum isolates of Pseudomonas sp. were found in pus samples (54.87%) followed by urine samples (32.92%), similar findings were reported by Khan et al. (2008)[13] isolated maximum pus sample (57.64%) followed by urine (24.2%). In another study by Mohanasoundaram (2011)[14] also showed higher isolates from pus samples followed by urine samples. A recent study by Nabamita Chaudhury et al., (2018)[15] reported maximum isolates were isolated from pus samples(42.62%). In the present study, maximum isolates were found in the age interval between 31 to 45 years (40.24%). Previous research findings by Mohanasoundaram (2011)[14] have reported the highest numbers of isolates of Pseudomonas in different age groups. So there is no significant relationship in the age of the patient with infection of Pseudomonas as it varies in different studies. In the present study, we showed the isolates of Pseudomonas sp. were maximum in male patients in the case of all types of samples. This outcome is consistent with a previous study by Khan et al., (2008),[13] which found that 61.78% of males and 38.22% of females were infected with Pseudomonas. Many studies have shown that infection with the Pseudomonas sp. is more prevalent in men than in women by Ullah et al., (2019).[16] In the present study, in-patients samples (65.85%) showed the maximum Pseudomonas isolates as compared to outpatients samples (34.15%). Mohanasoundaram, (2011)[14] reported in the previous study align with the current study as they registered the highest number of inpatient cases, with 35.86%, 57%, and 40.7% in 2008, 2009, and 2010 respectively. In present study sensitivity was seen 100% (n=82) in colistin and polymyxin-B, 86.58% (n=71) in meropenum, 82.92% (n=68) in piperacillin-tazobactam, 68.29% (N=56) in tobramycin,67.07% (n=55) in gentamicin, 64.63%(n=53) in amikacin, 58.58%(n=48) in piperacillin, 56.09%(n=46) in ceftazidime and 51.21%(n=42) in ciprofloxacin. And resistance was seen 80.48% (N=66) in co-trimoxazole, 82.92% (n=68) in cefixime, 59.75% (n=49) in cefoperazone/salbactam, 39.02%(n=32) in ciprofloxacin and 36.58%(n=30) in piperacillin. Similar results of sensitivity and resistance reported by Senthamarai S, 2014[17] and Gencer S, 2002[18] and various other research articles with slight variations in some antibiotics as it varies from one to another region based on the physiological and ecological conditions. MDR isolates are sensitive to antibiotics like colistin, polymyxin-B, and meropenem are reported in several studies for Pseudomonas sp. and other ESBL producing organisms like Klebsiella sp. by Negi S, 2020.[19] The total number of ESBL producing strains of Pseudomonas sp. in clinical samples was 30.48% in the present similar type of ESBL reported by Begum S, 2013.[20]
Conclusion
At the end of our study, we concluded that the most effective treatment for treating infections related to Pseudomonas sp. in the Dewas region is colistin, polymyxin-B, meropenem, and piperacillin-tazobactam. Maximum isolates of Pseudomonas sp. obtained from hospitalized patients indicated nosocomial infections. It is very necessary to conduct routine surveillance for resistance strains at regular intervals of time to protect many lives from harmful MDR strains. Our study is an attempt to regulate the use of antibiotics that are irrelevant and wasteful. It is also a public health concern to take adequate measures, maintain cleanliness and hygiene to reduce the spread of nosocomial infections. To minimize the spread of hospital-acquired infections, it is the primary responsibility of all health care staff and all clinicians, and all patients along with their relatives to facilitate adequate handwashing with soap or sanitization of all areas. We can protect many lives from life-threatening MDR strains in this way and also aim to keep our society healthy.
Source of Funding
None.
Conflict of Interest
None.
References
- J Chastre. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000. [Google Scholar] [Crossref]
- MD Obritsch, DN Fish, R MacLaren, Rose Jung. National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002. Antimicrob Agent Chemother 2004. [Google Scholar] [Crossref]
- AC Gales, RN Jones. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1997. [Google Scholar]
- R A Weinstein, R Gaynes, J R Edwards. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. ClinInfectious Dis 2005. [Google Scholar]
- R Ruimy, E Genauzeau, C Barnabe, A Beaulieu, M Tibayrenc, A Andremont. Genetic Diversity of Pseudomonas aeruginosa Strains Isolated from Ventilated Patients with Nosocomial Pneumonia, Cancer Patients with Bacteremia, and Environmental Water. Infect Immun 2001. [Google Scholar] [Crossref]
- M Ahmad, M Hassan, A Khalid, I Tariq, MH Asad, A Samad. Prevalence of Extended Spectrum beta-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan. BioMed Res Int 2016. [Google Scholar] [Crossref]
- T M Bauer, A W Kirby, W M Sherris, A Jc, W Bauer. Susceptibility testing by a standardized single disc method. Am J Clin 1966. [Google Scholar]
- JG Collee, AG Fraser, BP Marmion, A Simmons. . Mackie & McCarteny Practical Medical Microbiology 2008. [Google Scholar]
- M Cheesbrough. . Medical laboratories manual for tropical countries 2002. [Google Scholar]
- CW Washington, SD Allen, WM Janda, EW Koneman, GW Procop, PC Schreckenbergerpc. . Koneman's Color Atlas and Textbook of Diagnostic Microbiology 2006. [Google Scholar]
- . Performance Standards for Antimicrobial Susceptibility Testing; Approved standard- Twenty-Fifth Informational Supplement . 2015. [Google Scholar]
- K Lee, Y Chong, Hb Shin, YA Kim, D Yong, JH Yum. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobactet species. Clin Microbiol Infect 2001. [Google Scholar] [Crossref]
- JA Khan, Z Iqbal, SU Rahman, K Farzana, A Khan. Prevalence and resistance pattern of pseudomonas aeruginosa against various antibiotics. Pak J Pharm Sci 2008. [Google Scholar]
- KM Mohanasoundaram. The antibiotic resistance pattern in the clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J Clin Diagn 2008. [Google Scholar]
- N Chaudhury, S Mirza, RN Misra, R Paul, SS Chaudhuri, S Sen. Isolation and identification of various Pseudomonas species from distinct clinical specimens and the study of their antibiogram. Sch J App Med 2018. [Google Scholar]
- N Ullah, E Guler, M Guvenir, A Arıkan, K Suer. Isolation, identification, and antibiotic susceptibility patterns of Pseudomonas aeruginosa strains from various clinical samples in a University hospital in Northern Cyprus. Cyprus J Med 2019. [Google Scholar]
- S Senthamarai. Resistance Pattern of Pseudomonas aeruginosa in a Tertiary Care Hospital of Kanchipuram, Tamilnadu, India. J Clin Diagn Res 2014. [Google Scholar] [Crossref]
- S Gencer, O Ak, N Benzonana, A Batirel, S Ozer. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol 2002. [Google Scholar] [Crossref]
- S Negi, M Joshi, V Pahuja, L Bala. Antibiotic Resistance Pattern of Klebsiella sp. At Tertiary Care Centre From Garhwal Himalayan Region. Ann Int Med Den Res 2021. [Google Scholar] [Crossref]
- S Begum, A Salam, F Alam, N Begum, P Hassan, JA Haq. Detection of extended spectrum beta-lactamase in Pseudomonas spp. isolated from two tertiary care hospitals in Bangladesh. BMC Res Notes 2013. [Google Scholar] [Crossref]
- Introduction
- Materials and Methods
- Identification of Pseudomonas sp.
- Identification of Pseudomonas sp. was done by biochemical tests.
- Antibiotic susceptibility test
- Identification of extended-spectrum β-lactamase (ESBL) producing strains
- Ethical clearance
- Results
- Discussion
- Conclusion
- Source of Funding
- Conflict of Interest